Examining Iron Metabolism in Hemodialysis Patients
Study of Markers of Iron Metabolism and Their Relationship With Phosphocalcic and Hepatic Metabolism and Inflammation in Hemodialysis Patients
Ramsay Générale de Santé · NCT05586867
This study looks at how iron works in the bodies of people on hemodialysis to see how it relates to their overall health and other important minerals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ramsay Générale de Santé (other) |
| Locations | 1 site (Quincy-sous-Sénart) |
| Trial ID | NCT05586867 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the metabolism of iron in patients undergoing hemodialysis, focusing on the evolution of specific biomarkers such as hepcidin and erythroferrone. It will explore how these biomarkers relate to calcium phosphate metabolism, hepatic metabolism, and inflammation. By analyzing blood samples, the study seeks to provide insights into the conditions affecting iron absorption, metabolism, and storage in patients with advanced renal failure.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients undergoing hemodialysis who can provide informed consent.
Not a fit: Patients who are medically unstable, have severe anemia, or are participating in other conflicting clinical studies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the understanding of iron metabolism in hemodialysis patients, potentially leading to better management of related complications.
How similar studies have performed: While the specific biomarkers studied may not be routinely assessed, similar studies have indicated the importance of understanding iron metabolism in chronic kidney disease, suggesting potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult dialysis patient * Patient able to understand the information necessary for the study and having signed his written consent to participate * Affiliated patient or beneficiary of a social security scheme. Exclusion Criteria: * Medically unstable or frail patient * Patient with hemoglobin less than 7g/dl * Patient with HIV+ or AIDS, patient with replicating hepatitis B or C * Patient participating in another clinical study requiring an additional blood sample * Patient benefiting from legal protection measures (guardianship, guardianship, etc.) adult under guardianship, guardianship or other legal protection, deprived of freedom by judicial or administrative decision * Pregnant, breastfeeding or parturient woman
Where this trial is running
Quincy-sous-Sénart
- Hôpital Privé Claude Galien — Quincy-sous-Sénart, France (RECRUITING)
Study contacts
- Study coordinator: Jean-François Oudet
- Email: jeanfrancois.oudet@free.fr
- Phone: 0683346567
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Iron Metabolism Disorders, Calcium Phosphate Metabolism, Hepatic Metabolic Disorders, Hemodialysis Complication